ReForm gets patents for therapeutic protein formulations

By The Science Advisory Board staff writers

April 10, 2020 -- ReForm Biologics has received a U.S. patent for therapeutic protein formulations that reduce protein aggregation and stabilize proteins during storage.

The formulations include a new class of stabilizers to serve as an alternative to traditional surfactants. The company has licensed its ReForm excipients used in biotherapeutic formulations to MilliporeSigma.

ReForm also announced its first patent in Japan for technology to reduce the viscosity of highly concentrated antibody solutions. The excipient technology will enable scientists to more effectively formulate solutions for more preferable delivery routes, the company noted.

MilliporeSigma awarded U.S. patent for new CRISPR technology
MilliporeSigma announced that the U.S. Patent and Trademark Office has granted the company's patent for CRISPR-chrom technology. This award is the second...
Shortage of RNA extraction kits threatens coronavirus testing
The weak link in the U.S. response to diagnostic testing for the novel coronavirus SARS-CoV-2 could be a shortage of RNA extraction kits. Fortunately,...
MilliporeSigma launches Lanexo software at Pittcon 2020
MilliporeSigma launched its Lanexo software for lab inventory, safety, and compliance management at the Pittcon meeting in Chicago on March 3. The new...
MilliporeSigma to make Elypta liquid biopsy kits
MilliporeSigma has signed an agreement with Swedish molecular diagnostics company Elypta to be the contract manufacturer for Elypta's clinical diagnostic...
ReForm Biologics, MilliporeSigma ink license agreement
ReForm Biologics and MilliporeSigma have signed a licensing agreement to develop and market excipients used for biotherapeutic applications. The agreement...

Copyright © 2020

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter